MergerMay 20, 2026, 05:06 PM
Liminatus Pharma to Merge with InnocsAI; Acquires Oncology Pipeline
AI Summary
Liminatus Pharma, Inc. has entered into a Merger Agreement with InnocsAI LLC, under which InnocsAI will merge into a new wholly-owned subsidiary of Liminatus Pharma. The acquisition involves an aggregate consideration of 1.6 billion shares of Liminatus Pharma common stock, valued at $0.20 per share, along with contingent value rights representing 20% of future net proceeds from the acquired assets. This strategic move significantly expands Liminatus Pharma's pipeline with oncology-focused biologic and cellular therapy programs, including advanced CAR-T candidates like IBC101 and INC101, designed to address limitations in current cancer treatments.
Key Highlights
- Liminatus Pharma entered a Merger Agreement with InnocsAI LLC on May 17, 2026.
- InnocsAI will merge into a new wholly-owned Delaware subsidiary of Liminatus Pharma.
- Aggregate consideration for InnocsAI members is 1,600,000,000 shares of Liminatus Pharma common stock.
- Shares are issued at a price of $0.20 per share.
- Contingent value rights represent 20% of net proceeds from future strategic sale/out-license of acquired assets.
- Acquired assets include oncology-focused biologic and cellular therapy programs, centered on CAR-T and antibody technologies.
- Pipeline includes IBC101 (CD19xCD22 bivalent CAR-T for B-cell malignancies) and INC101 (MSLNxCD276 bicistronic CAR-T for solid tumors).
- IBC101 has received authorization for a Phase 1/2a clinical study in South Korea.
Price Impact
More from LIMN